Covidien plc Form 425 August 25, 2014

Omar Ishrak
Chairman and CEO
2014 Annual Shareholders Meeting
August 21, 2014
Filed by Medtronic, Inc. (SEC File No.: 001-07707)
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Covidien plc
Form S-4 File No.: 333-197406

Date: August 22, 2014

NO OFFER OR SOLICITATION

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or lor subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition, the mer be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

IMPORTANT ADDITIONAL INFORMATION

Medtronic Holdings Limited, which will be renamed Medtronic plc (New Medtronic), has filed with the Securities and Excregistration statement on Form S-4 that includes the preliminary Joint Proxy Statement of Medtronic, Inc. (Medtronic) and constitutes a preliminary Prospectus of New Medtronic. The registration statement is not complete and will be further amended to make available to their respective shareholders the final Joint Proxy Statement/Prospectus (including the Scheme) in connect INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PRELIMINARY JOINT PROXY STATEMENT/PRORELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILA IMPORTANT INFORMATION ABOUT MEDTRONIC, COVIDIEN, NEW MEDTRONIC, THE TRANSACTIONS AND Fable to obtain free copies of the preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed Medtronic, Medtronic and Covidien through the website maintained by the SEC at www.sec.gov. In addition, investors and shacopies of the preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed by Medtronic are contacting Medtronic Investor Relations at investor relations@medtronic.com or by calling 763-505-2696, and will be able to preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed by Covidien by contacting Co

Edgar Filing: Covidien plc - Form 425

investor.relations@covidien.com or by calling 508-452-4650.

PARTICIPANTS IN THE SOLICITATION

Medtronic, New Medtronic and Covidien and certain of their respective directors and executive officers and employees may be solicitation of proxies from the respective shareholders of Medtronic and Covidien in respect of the transactions contemplated Statement/Prospectus. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the s shareholders of Medtronic and Covidien in connection with the proposed transactions, including a description of their direct or holdings or otherwise, will be set forth in the final Joint Proxy Statement/Prospectus when it is filed with the SEC. Information and executive officers is contained in Medtronic s Annual Report on Form 10-K for the fiscal year ended April 25, 2014 and it dated July 11, 2014, which are filed with the SEC. Information regarding Covidien s directors and executive officers is contain Form 10-K for the fiscal year ended September 27, 2013 and its Proxy Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC. Information Statement on Schedule 14A, dated January 24, 2014, which are filed

Statements contained in this communication that refer to New Medtronic s, Medtronic's and/or Covidien s estimated or antice estimated synergies, or other non-historical facts are forward-looking statements that reflect Medtronic's and/or Covidien s cut trends and information as of the date of this communication. Forward-looking statements generally will be accompanied by we believe, plan, could, should, estimate, expect, forecast, outlook, guidance, intend, may, might project, or other similar words, phrases or expressions. It is important to note that these goals and expectations are not predict Actual results may differ materially from current expectations depending upon a number of factors affecting New Medtronic's Covidien s business and risks associated with the proposed transactions. These factors include, among others, the inherent uncorrections; restructuring in connection with, and successful close of, the Covidien acquisition; subsequent integration of the Covidien acquisition;

Edgar Filing: Covidien plc - Form 425

to recognize the anticipated synergies and benefits of the Covidien acquisition; the risk that the required regulatory approvals f not obtained, are delayed or are subject to conditions that are not anticipated; the anticipated size of the markets and continued

Covidien's products; the impact of competitive products and pricing; access to available financing (including financing for the Medtronic or Covidien debt) on a timely basis and on reasonable terms; the risks of fluctuations in foreign currency exchange normally incident to the medical device industry, including competition in the medical device industry; product liability claims timing or outcome of pending or future litigation or government investigations; variability of trade buying patterns; the timing launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or adverse pricing movement; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufact in supply; product quality problems; the availability and pricing of third-party sourced products and materials; risks associated commercial insurance; successful compliance with governmental regulations applicable to New Medtronic s, Medtronic's and and/or businesses; changes in the laws and regulations, affecting among other things, pricing and reimbursement of pharmaceu policy changes; risks associated with international operations; changes in tax laws or interpretations that could increase New M Covidien s consolidated tax liabilities, including, if the transaction is consummated, changes in tax laws that would result in N domestic corporation for United States federal tax purposes; the loss of key senior management or scientific staff; and such other detailed in Medtronic's periodic public filings with the SEC, including but not limited to Medtronic's Annual Report on Form 1 25, 2014, in Covidien s periodic public filings with the SEC, including but not limited to Covidien s Annual Report on Form September 27, 2013, and from time to time in Medtronic's and Covidien s other investor communications. Except as expressly Medtronic and Medtronic disclaims any intent or obligation to update or revise these forward-looking statements.

STATEMENT REQUIRED BY THE IRISH TAKEOVER RULES

The directors of Medtronic accept responsibility for the information contained in this document. To the best of the knowledge

Edgar Filing: Covidien plc - Form 425

Medtronic (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in does not omit anything likely to affect the import of such information.

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

Medtronic Executive Committee

Omar

Ishrak

Chairman

and Chief

Executive Officer

Hooman

Hakami

EVP and Group

President,

Diabetes

Geoff

Martha

SVP, Chief

Integration

Officer

Chris

O Connell

Edgar Filing: Covidien plc - Form 425

VP, South Asia Takashi Shimada VP and President, Japan Rob ten Hoedt EVP and President, Europe, Middle East, Africa and Canada Chris Lee VP and President, Greater China Katie Szyman SVP, Channel Strategies Luann Pendy SVP, Global Quality James Hogan VP and President, Latin America Michael Genau SVP and President, **United States** Mike Coyle

EVP and Group President, Cardiac and Vascular Gary Ellis

EVP and Group President, Restorative Therapies Milind Shah

Edgar Filing: Covidien plc - Form 425

EVP and

Chief Financial

Officer

Stephen

Oesterle,

M.D.

SVP, Medicine

and

Technology

Joon

Hurh

VP and

President,

Asia Pacific

Rick

Kuntz, M.D.

SVP and Chief

Scientific, Clinical

and Regulatory

Officer

Brad

Lerman

SVP and General

Counsel,

Corp. Security

Carol

Surface

SVP and

Chief Human

Resources

Officer

Medtronic Board of Directors Michael Leavitt Founder and Chairman, **Leavitt Partners** James Lenehan Financial Consultant and Retired Vice Chairman and President, Johnson & Johnson Denise O Leary Private Venture Capital Investor Preetha Reddy, M.D. Managing Director, Apollo Hospitals Enterprise Limited Robert Pozen Chairman, MFS Investment Management Shirley Ann Jackson, Ph.D.

Edgar Filing: Covidien plc - Form 425

President,

Rensselaer Polytechnic Institute

Omar Ishrak

Chairman

and Chief Executive Officer

Richard Anderson

Chief Executive Officer,

Delta Air Lines, Inc.

Scott Donnelly

Chairman, President and Chief

Executive Officer, Textron, Inc.

Kendall Powell

Chairman and Chief

Executive Officer, General

Mills, Inc.

Co-Founder and Director Emeritus Dr. Earl E. Bakken

Insert Bakken Invitation Video

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

Brad Lerman SVP, General Counsel & Corporate Secretary Business Items and Balloting

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

Universal Healthcare Needs Improve Clinical Outcomes Expand Access Optimize Cost and Efficiency

Economic Value

Globalization

Strategies

Strategies

Therapy

Innovation

Universal HC needs

Universal HC needs

Improve clinical

outcomes

Expand access

Optimize cost

and efficiency

Strategies to Address Healthcare Needs

Therapy Innovation Highlights: MiniMed 530G

Important breakthrough toward artificial pancreas

Mimics certain functionalities of a healthy pancreas

Automatically stops insulin delivery if glucose levels fall below threshold MiniMed® 530G System with the Enlite® Sensor

Creating Value Through Surgical Synergy Delivering better surgical outcomes through procedural innovations that integrate our enabling technologies, surgical tools, device implants and therapy expertise

Our Neuroscience Portfolio Is Deep, Broad and Differentiated Enabling technologies and surgical tools
Brain surgeries rapidly advancing, with functional restoration (i.e. DBS)
BRAIN
Procedural engine of Neurosurgery;
>70% perform Spine surgery

Only company with leading position in all three therapeutic categories

1,000+ U.S. neurosurgeons utilize technology from all three Medtronic divisions NEUROSURGERY TECHNOLOGY

Edgar Filing: Covidien plc - Form 425

SPINE & PAIN MDT s Unique Position

Therapy Innovation Highlights: Reveal LINQ

87% smaller than our previous device

Continuously monitors heart rate and rhythm

Helps diagnose cardiac arrhythmias

Increases physician and patient acceptance Reveal LINQ Insertable Cardiac Monitor

Patient Video Roll-in: Reveal LINQ

Therapy Innovation Highlights: CoreValve System

Received FDA approval for Extreme-Risk and High-Risk patients

Differentiated therapy for severe aortic stenosis patients too ill or frail for open-heart surgery

Superior valve performance and lower mortality rates than traditional surgery

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

Developing Tailored Solutions to Address Market-Specific Needs & Expand Access Shruti Kidney Dialysis

Market development

Channel management

Public and private partnerships

Value segment products and business models

Global Health Initiative Premium Value Underserved

Innovative Kidney Hemodialysis Program for Emerging Markets

End stage renal disease has high prevalence worldwide and is disproportionately costly

Reduces infrastructure and cost

Uses 90% less water

Small, highly flexible, portable size (20kg) improves patient access Novel Hemodialysis System

Shruti Program for the Underserved More than 35,000 patients screened 10% identified for follow-up care Delivers screening, diagnosis and treatment for chronic ear infections 150 surgeries performed

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

Building An Integrated Health Solutions Business
Cath Lab Managed
Services
Creating efficiency along the care continuum
Cardiocom: Patient care coordination from
hospital to home
Establishing long-term value-based partnerships
Cath Lab Managed Services: Helping hospitals more
effectively manage cath labs and ORs
Increasing global scale and broadening our product
offering to drive future growth

Omar Ishrak Chairman and CEO 2014 Annual Shareholders Meeting August 21, 2014

FY14 Sales and Net Earnings Results

Revenue

\$17.0 billion

% Growth, as reported

+3%

% Growth, constant currency

+4%

Reconciliation available on Medtronic s website at www.medtronic.com.

GAAP Net Earnings

\$3.1 billion

% Decline

-12%

GAAP Diluted EPS

\$3.02

% Decline

-10%

Non-GAAP Net Earnings

\$3.9 billion

Edgar Filing: Covidien plc - Form 425

% Growth 0%
Non-GAAP Diluted EPS \$3.82
% Growth +2%

Q1 FY15 Sales and Net Earnings Results

Revenue

\$4.3 billion

% Growth, as reported

+5%

% Growth, constant currency

+4%

Reconciliation available on Medtronic s website at www.medtronic.com.

GAAP Net Earnings

\$871 million

% Decline

-9%

GAAP Diluted EPS

\$0.87

% Decline

-6%

Non-GAAP Net Earnings

\$934 million

Edgar Filing: Covidien plc - Form 425

% Growth +4% Non-GAAP Diluted EPS \$0.93 % Growth +6%

```
+100%
+75%
+65%
3-Year Stock Performance: MDT Up ~100%
$64.15
$64.15
$32.03
$32.03
-20%
0%
20%
40%
60%
80\%
100%
120%
Medtronic Inc
```

DOW JONES US MEDICAL EQUIPMENT

Medtronic to Acquire Covidien Creates the premier global medical technology and services company with unmatched breadth and patient reach

The Medtronic Mission: A Shared Sense of Purpose
To contribute to human welfare alleviate pain,
restore health, and extend life
To direct our growth in the areas of maximum strength
and ability to continuously build on these areas through
education and knowledge
To strive without reserve for the greatest reliability and
quality
to be recognized as a company of dedication,
honesty, integrity, and service
To make a fair profit
To recognize the personal worth of employees
To maintain good citizenship as a company.

A Strong Strategic Fit

&

Uniquely positioned to expand our industry-leading franchises through our three differentiated strategies:

Economic Value:

Becoming a leader in value-based

healthcare by incorporating EV into our DNA

Globalization:

Addressing the inequities

in healthcare access globally

Therapy Innovation:

Delivering strong launch

cadence of meaningful therapies and procedures

Three Key Benefits for Medtronic and Covidien Therapy Innovation Therapy Innovation

1.

Strengthen and enhance Peripheral Vascular and Neuroscience portfolios

2

Leverage adjacencies in Medtronic Surgical Technologies and Covidien Surgical Solutions

3. Accelerate market adoption of early stage Covidien therapies

countries

150

+

locations

300

+

combined

EM revenue

\$3.7B

Combined Company Immediately Accelerates Ability

to Expand Global Access

Broader presence facilitates more rapid expansion

Covidien products such as surgical tools and capital equipment are adopted earlier in hospitals, becoming a base for Medtronic chronic disease therapies

Combined R&D and manufacturing breadth globally enables broader government partnerships

Complementary Solutions Create Opportunities for Robust Integrated Health Offerings
Value in post-acute settings
Value in post-acute settings
Value in hospital efficiencies
Value in hospital efficiencies

Combination Results in Strategic Diversification

Surgical

Surgical

Solutions

Solutions

Respiratory &

Respiratory &

Patient Care

Patient Care

Spine

Spine

Cardiac Rhythm

Cardiac Rhythm

& Heart Failure

& Heart Failure

Coronary

Coronary

& Structural

Edgar Filing: Covidien plc - Form 425

& Structural

Heart Heart

Diabetes

Diabetes

Urological, urogynecological and gastroenterological

Diagnostics and solutions

Diabetes

Neurological

Spinal and orthopedic

Ear, nose and throat

Structural heart

Endovascular

Coronary

Cardiac rhythm

Severe spasticity

Parkinson s disease

Essential tremor

Dystonia*

Hydrocephalus

Obsessive-compulsive disorder*

Brain tumors and lesions

Chronic pain

Edgar Filing: Covidien plc - Form 425

Subdural hematomas Cranial trauma Cervical degenerative disc disease **Scoliosis** Degenerative disc disease Spinal fracture Lumbar spinal stenosis Tibial fractures Orthopedic trauma Sinus diseases Thyroid conditions Otologic disorders Sleep-disordered breathing Pediatric conditions Ménière s disease Heart valve disease Congenital heart disease Overactive bladder and urinary retention Nausea and vomiting associated with gastroparesis* Fecal incontinence Atrial fibrillation Slow heart rates (bradycardia) Fast heart rates (tachycardia) Heart failure Asymptomatic heart rates Cardio-Pulmonary Acute ischemic stroke Brain aneurysm Vascular embolization Thyroidectomy Airway access Interventional GI Cholecystectomy

Appendectomy Barrett s esophagus

Capsule endoscopy

Bariatric bypass and sleeves

Colon resection

Hemorrhoidectomy

Nutrition delivery

Hysterectomy

Fibroids

Salpingo-oophorectomy (sterilization)

CO2 and Respiration

Consciousness

Oximetry (pulse and bi-spectral)

Skin integrity

Edgar Filing: Covidien plc - Form 425

the
United
States
the
effectiveness
for
this
use
has
not been demonstrated
Coronary artery disease
Interventional lung
Lobectomy/resection
Mechanical ventilation
Further Expanding Our Comprehensive Portfolio

Arterial

Venous insufficiency

Patient & caregiver safety

* Humanitarian

device in

Deep vein thrombosis

End stage renal disease Peripheral vascular disease Aortic aneurysms

Medtronic will also continue to be subject to all U.S. tax laws:

Federal

35%

tax

rate

on

U.S.

taxable

income

State

up


to

12%

depending

on

Edgar Filing: Covidien plc - Form 425



each state s

Local up to 9.25% depending

on

corporate tax rate

Continued Focus on Innovation Leadership Medtronic commits \$10B of incremental technology investments in U.S. over next 10 years *Over last 10 years Acquisition and venture investments: \$8.3B+ invested 80+ U.S.-based companies* \$8.3B+ Clinical research: \$450M invested annually in clinical trials and studies (~76% in the U.S.) \$450M

R&D: \$11B+ invested in the U.S.* \$11B+

Investing in U.S. Technology and Partnerships

TYRX

Acquisition

Sanofi

Strategic Alliance

Visualase

Acquisition

Combination antibiotic

drug & implanted

medical devices

Diabetes partnership to

improve patient

experience and outcomes

MRI-guided laser ablation

technology expands

neuroscience leadership

Corventis

Acquisition

Mobile cardiac telemetry system provides continuous monitoring

Covidien Transaction Summary

Acquisition of Covidien for \$42.9 billion, in cash (\$16.1 billion) and Medtronic stock (\$26.8 billion based on Medtronic s closing stock price

on

June

13,

2014,

the

last

trading

day

prior

to

the

announcement

of

the

acquisition)

Represents per share consideration for Covidien shareholders of \$35.19 in cash and 0.956 shares of new Medtronic shares

Offer represents a 29% premium to Covidien s last closing share price on June 13, 2014

Transaction

Terms

Transaction

Structure

Formation

of

new

Irish-domiciled

entity;

current

headquarter

operations

remain intact in Minnesota

Transaction taxable, for U.S. federal income tax purposes, to Medtronic and Covidien shareholders
Timing

Closing expected in fourth calendar quarter of 2014 or early 2015

Subject to regulatory approvals

Subject to Medtronic and Covidien shareholder approvals

Special Excise Tax Is an Additional Tax

This excise tax is in addition to the tax on the exchange of shares and is

not

applicable

to

any

other

employees

or

retirees

of

the

company.

It

is a

tax

applicable

only
to
Section
16b
officers
of
Medtronic
as
well
as
members
of
the Board of Directors.
Because this excise tax is separate and incremental to the tax on the
exchange
of
shares
that
applies
for
all
shareholders,
including
directors and
officers of the company, Medtronic will assist directors and officers using a tax
"gross-up."
This will result in those shareholders being in the same tax position
as
all other shareholders.

Transforming Healthcare Around the World to Improve More Lives
Together:
\$27 Billion Healthcare Leader
87,000+ Employees
Life-Changing Impact for Millions
of Patients

Q&A